[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558448":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":37,"centralContacts":42,"locations":51,"responsibleParty":125,"collaborators":33,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":33,"eligibilityCriteria":133,"healthyVolunteers":129,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":33,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":54,"whyStopped":33,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Solifenacin 5 mg + add-on solifenacin 5 mg","EXPERIMENTAL","Group 1A: Solifenacin 5 mg for 6 weeks, and if non-complete response after 6 weeks add-on solifenacin 5 mg for 12 weeks.",[13],"Drug: Solifenacin",{"label":15,"type":10,"description":16,"interventionNames":17},"Solifenacin 5 mg + add-on mirabegron 25 mg","Group 1B: Solifenacin 5 mg for 6 weeks, and if non-complete response after 6 weeks add-on mirabegron 25 mg for 12 weeks.",[13,18],"Drug: Mirabegron",{"label":20,"type":10,"description":21,"interventionNames":22},"Mirabegron 25 mg + ad-on mirabegron 25 mg","Group 2A: Mirabegron 25 mg for 6 weeks, and if non-complete response after 6 weeks add-on mirabegron 25 mg for 12 weeks.",[18],{"label":24,"type":10,"description":25,"interventionNames":26},"Mirabegron 25 mg + add-on solifenacin 5 mg","Group 2B: Mirabegron 25 mg for 6 weeks, and if non-complete response after 6 weeks add-on solifenacin 5 mg for 12 weeks.",[13,18],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Solifenacin","According to randomization.",[24,15,9],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"Mirabegron",[20,24,15],[38],{"name":39,"affiliation":40,"role":41},"Luise Borch, MD, PhD","Department of Pediatric and Adolescent Medicine, Gødstrup Hospital","STUDY_DIRECTOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":33,"email":47},"Ann-Kristine Mandøe Svendsen, MD","CONTACT","+45 78430408","ankrso@rm.dk",{"name":39,"role":45,"phone":49,"phoneExt":33,"email":50},"+45 78433654","luiseborch@rm.dk",[52,70,86,99,112],{"facility":53,"status":54,"city":55,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Department of Pediatric and Adolescent Medicine, Aalborg University Hospital","RECRUITING","Aalborg","9000","Denmark","DK",{"type":60,"coordinates":61},"Point",[62,63],9.9187,57.048,{"lat":63,"lon":62},[66],{"name":67,"role":45,"phone":68,"phoneExt":33,"email":69},"Søren Hagstrøm, Professor","+45 97663374","soha@rm.dk",{"facility":71,"status":54,"city":72,"state":73,"zip":74,"country":57,"countryCode":58,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Department of Pediatric and Adolescent Medicine, Aarhus University Hospital","Aarhus","Aarhus N","8200",{"type":60,"coordinates":76},[77,78],10.21076,56.15674,{"lat":78,"lon":77},[81,84],{"name":82,"role":45,"phone":33,"phoneExt":33,"email":83},"Konstantinos Kamperis, MD, PhD","konskamp@rm.dk",{"name":44,"role":85,"phone":33,"phoneExt":33,"email":33},"SUB_INVESTIGATOR",{"facility":87,"status":54,"city":88,"state":88,"zip":89,"country":57,"countryCode":58,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Department of Pediatric and Adolescent medicine, Esbjerg Hospital","Esbjerg","6700",{"type":60,"coordinates":91},[92,93],8.45187,55.47028,{"lat":93,"lon":92},[96],{"name":97,"role":45,"phone":33,"phoneExt":33,"email":98},"Linda Kuhne-Qvist, MD","Linda.Kuhne-qvist2@rsyd.dk",{"facility":40,"status":54,"city":100,"state":100,"zip":101,"country":57,"countryCode":58,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Herning","7400",{"type":60,"coordinates":103},[104,105],8.97662,56.13615,{"lat":105,"lon":104},[108,110],{"name":39,"role":45,"phone":49,"phoneExt":33,"email":109},"luise.borch@rm.dk",{"name":44,"role":111,"phone":33,"phoneExt":33,"email":33},"PRINCIPAL_INVESTIGATOR",{"facility":113,"status":54,"city":114,"state":114,"zip":115,"country":57,"countryCode":58,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Department of Pediatric and Adolescent Medicine, Kolding Hospital","Kolding","6000",{"type":60,"coordinates":117},[118,119],9.47216,55.4904,{"lat":119,"lon":118},[122],{"name":123,"role":45,"phone":33,"phoneExt":33,"email":124},"Louise Winding, MD","louise.winding1@rsyd.dk",{"type":126,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100558448","phase-3-efficacy-of-solifenacin-mirabegron-and-combination-therapy-in-children-with-daytime-urinary-incontinence-bedry-100558448",false,"NCT06551246","Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Overactive Bladder and Daytime Urinary Incontinence (BeDry)","Inclusion Criteria:\n\n1. The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation of any study specific procedures.\n2. Age 5 to 14 years (inclusive) at the time of inclusion.\n3. Overactive bladder as per International Children's Continence Society criteria\n4. At least 2 daytime urinary incontinence episodes per week\n5. Inadequate effect of at least 4 weeks urotherapy (non-pharmacological treatment)\n6. No previous treatment with solifenacin, mirabegron or bladder\u002Fsphincter botulinum toxin injections\n7. No current constipation as per ROME IV criteria or fecal incontinence (laxative treatment is accepted)\n8. Per investigator's judgment, the participant can swallow or can learn to swallow study medication\n\nExclusion Criteria:\n\n1. Inability of the patent(s) or legal guardian(s) to understand the Danish written and oral information\n2. Known or suspected hypersensitivity to study medication\n3. Any contraindication to the use of the study medication\n4. Known urogenital anatomical abnormalities affecting lower urinary tract function\n5. Known kidney or bladder stones\n6. Known diabetes insipidus\n7. Ongoing symptomatic urinary tract infection\n8. Recurrent urinary tract infection or ongoing prophylactic antibiotic treatment\n9. Known QTc prolongation, QTc \\>460 ms, or risk of QTc prolongation (hypokalaemia, exercise-induced syncope, or familial long QT syndrome)\n10. Other significant electrocardiogram abnormalities\n11. Known hypertension\n12. ≤3 daily voiding, evaluated by 48-hour frequency-volume chart\n13. Uroflowmetry suggestive of other pathology than overactive bladder (staccato-shaped, interrupted-shaped, or plateau-shaped curve)\n14. Post-void residual \\>50 ml after double voiding\n15. Dipstick haematuria (≥2+ erythrocytes) or macroscopic haematuria\n16. Pregnancy or breastfeeding\n17. Female subjects of childbearing potential\n18. Ongoing constipation according to Rome IV-criteria which is intractable to medication or fecal incontinence\n19. Inability to swallow study medication\n20. Use of any medication during study period, except permitted medication","ALL","5 Years","14 Years",{"count":138,"type":139},236,"ESTIMATED","INTERVENTIONAL",[142],"PHASE3","The primary objective is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose.\n\nIn total, 236 children diagnosed with daytime urinary incontinence will be randomized 1:1:1:1 to one of four treatment groups. Total pharmacological treatment period will be 18 weeks.",[145],"Urinary Incontinence in Children",[147,148,149,150,30,35],"Urinary incontinence","Daytime urinary incontinence","Overactive bladder","Children","2026-06-04",{"date":153,"type":154},"2026-06-08","ACTUAL",{"date":156,"type":154},"2024-06-27",{"date":158,"type":139},"2027-12-01",{"name":5,"class":6},5]